Shares of Moderna (NASDAQ: MRNA) climbed 8.5% on Friday following Johnson & Johnson's (NYSE: JNJ) disappointing coronavirus vaccine news.
Johnson & Johnson said that interim data from the phase 3 trial of its single-dose vaccine candidate had shown it to be 66% effective at preventing moderate to severe cases of COVID-19. However, the level of protection was lower in areas where new strains of the coronavirus are more prevalent, suggesting that it could be less effective at protecting against them.
Moderna's stock price rose sharply on Friday. Image source: Getty Images.
Source Fool.com